Document is current
Any future updates will be listed below
-
Authors
Protasoni, Margherita
López-Polo, Vanessa https://orcid.org/0000-0001-6165-2510
Stephan-Otto Attolini, Camille
Brandariz, Julian https://orcid.org/0009-0006-4316-3952
Herranz, Nicolas
Mateo, Joaquin
Ruiz, Sergio https://orcid.org/0000-0002-0177-6965
Fernandez-Capetillo, Oscar https://orcid.org/0000-0002-2690-6885
Kovatcheva, Marta https://orcid.org/0000-0002-2536-1043
Serrano, Manuel https://orcid.org/0000-0001-7177-9312
-
Funding
Funding for this research was provided by:
EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (HORIZON-MSCA-2021-PF-01)
Ministerio de Ciencia, Innovación y Universidades (FPU-18/05917)
Fundación Científica Asociación Española Contra el Cáncer (PRYCO211023SERR)
MEC | Instituto de Salud Carlos III (CP19/00170)
NIH Intramural Research Program
Barcelona Institute of Science and Technology
European Molecular Biology Organization (POSTD18020SERR)
'la Caixa' Foundation (PRYCO211023SERR)
Centres de Recerca de Catalunya (Grup de Recerca consolidat 2017 SGR 282)
- License Information
-
More Information
Article History
Received: 20 October 2023
Revised: 23 August 2024
Accepted: 16 September 2024
First Online: 24 October 2024
Disclosure and competing interests statement
: MK has ongoing or completed research contracts with Galapagos NV, Rejuveron Senescence Therapeutics, and mesoestetic®. MS is shareholder of Senolytic Therapeutics, Inc., Life Biosciences, Inc., Rejuveron Senescence Therapeutics, AG, and Altos Labs, Inc. MS has been consultant, until the end of 2022, of Rejuveron Senescence Therapeutics, AG, and Altos Labs, Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
